SCHEMBL1305151

SCHEMBL1305151

N#Cc1ccc(C(N)=NN)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NOS3 P29474 2/20 0.53
▸ NOS1 P29475 2/20 0.53
▸ PARP15 Q460N3 1/20 0.47
▸ PARP10 Q53GL7 1/20 0.47
▸ PARP2 Q9UGN5 1/20 0.47
▸ CA2 P00918 3/20 0.47
▸ CA1 P00915 2/20 0.47
▸ CA12 O43570 1/20 0.44
▸ CA3 P07451 1/20 0.44
▸ CA6 P23280 1/20 0.44
▸ CA9 Q16790 1/20 0.44
▸ CA14 Q9ULX7 1/20 0.44
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ GSK3B P49841 2/20 0.42
▸ MAOA P21397 1/20 0.42
▸ MAOB P27338 1/20 0.42
▸ POLB P06746 1/20 0.41
▸ LOXL2 Q9Y4K0 1/20 0.40
▸ MMP3 P08254 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1160894 0.84 NOS3 (0.50) NOS3NOS1PARP15PARP10PARP2
SCHEMBL4947766 0.84 NOS3 (0.50) NOS3NOS1PARP15PARP10PARP2
SCHEMBL13013670 0.80 CA2 (0.48) NOS3NOS1PARP15PARP10PARP2
SCHEMBL16930794 0.76 PARP15 (0.46) NOS3NOS1PARP15PARP10PARP2
SCHEMBL1305251 0.76 GSK3B (0.49) NOS3NOS1GSK3BPOLBIDO1
SCHEMBL17396097 0.76 CYP2D6 (0.62) NOS3NOS1PARP15PARP10PARP2
SCHEMBL322070 0.73 PARP15 (0.78) NOS3NOS1PARP15PARP10PARP2
SCHEMBL15902206 0.73 LMNA (0.52) NOS3NOS1PARP15PARP10PARP2
SCHEMBL7532498 0.73 CA2 (0.50) NOS3NOS1PARP15PARP10PARP2
Hydrochloric Acid SCHEMBL5860266 0.71 PRSS1 (0.54) NOS3NOS1PARP15PARP10PARP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8053573-B2 Monomer 5, 6-diphenyl-1.2.4-traizinic derivatives and the use thereof PIERRE FABRE DERMO-COSMETIQUE (FR) 2011-11-08 — — US disclosed
EP-1751122-B1 MONOMER 5,6-DIPHENYL-1,2,4-TRIAZINIC DERIVATIVES AND THE USE THEREOF FABRE PIERRE DERMO COSMETIQUE (FR) 2010-03-17 — — EP disclosed
US-20080299055-A1 Monomer 5, 6-Diphenyl-1.2.4-Traizinic Derivatives and the Use Thereof PIERRE FABRE DERMO-COSMETIQUE (FR) 2008-12-04 — — US disclosed
EP-1751122-A1 MONOMER 5,6-DIPHENYL-1,2,4-TRIAZINIC DERIVATIVES AND THE USE THEREOF Pierre Fabre Dermo-Cosmetique (FR) 2007-02-14 — — EP disclosed
WO-2005121108-A1 MONOMER 5,6-DIPHENYL-1,2,4-TRIAZINIC DERIVATIVES AND THE USE THEREOF PIERRE FABRE DERMO-COSMETIQUE (FR) 2005-12-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080299055-A1 Monomer 5, 6-Diphenyl-1.2.4-Traizinic Derivatives and the Use Thereof POT1, TELO2, CLIC1 NOS3 3186/4885NOS1 2285/4885PARP15 621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback